Wedbush initiated coverage of Opus Genetics (IRD) with an Outperform rating and $8 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics’ New Study on Vision Improvement: What Investors Need to Know
- Opus Genetics Advances Genetic Therapy for Rare Eye Conditions
- Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update
- Opus Genetics: Promising Gene Therapy Developments and Strategic Advancements Drive Buy Rating
- Opus Genetics initiated with a Buy at Chardan